References
- Benencia F, Muccioli M, Alnaeeli M. (2014). Perspectives on reprograming cancer-associated dendritic cells for anti-tumor therapies. Front Oncol, 4, 72. doi:10.3389/fonc.2014.00072.
- Bos PD. (2016). TREG cells in cancer: Beyond classical immunological control. Immunol Invest, 45, 721–728.
- Bos PD, Plitas G, Rudra D, et al. (2013). Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med, 210(11), 2435–2466. doi:10.1084/jem.20130762.
- Li Q, Egilmez NK. (2016). Ontogeny of tumor-associated CD4+CD25+Foxp3+ T-regulatory cells. Immunol Invest, 45, 729–745.
- Li Q, Virtuoso LP, Anderson CD, Egilmez NK. (2015). Regulatory rebound in IL-12-treated tumors is driven by uncommitted peripheral regulatory T cells. J Immunol (Baltimore, MD: 1950), 195(3), 1293–1300. doi:10.4049/jimmunol.1403078.
- Liu W, Almo SC, Zang X. (2016). Co-stimulate or co-inhibit regulatory T cells, which side to go? Immunol Invest, 45, 813–831. doi: 10.1080/08820139.2016.1186690.
- Manjili MH. (2014). The inherent premise of immunotherapy for cancer dormancy. Cancer Res, 74(23), 6745–6749.
- Manjili MH, Butler SE. (2016). Role of Tregs in cancer dormancy or recurrence. Immunol Invest, 45, 759–766.
- Monzavi-Karbassi B, Hennings LJ, Artaud C, et al. (2007). Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. Vaccine, 25(16), 3022–3031. doi:S0264-410X(07)00039-4.
- Monzavi-Karbassi B, Jousheghany F, Kieber-Emmons T. (2016). Tumor-associated glycans and Tregs in immunogenicity of an autologous cell-based vaccine. Immunol Invest, 45, 746–758.
- Payne KK. (2016). Lymphocyte-mediated immune regulation in health and disease: The Treg and γδ T cell co-conspiracy. Immunol Invest, 45, 767–775.
- Payne KK, Keim RC, Graham L, et al. (2016). Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells. J Leukoc Biol, 100(3), 625–35. doi:jlb.5A1215–580R.
- Payne KK, Zoon CK, Wan W, et al. (2013). Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/Neu reactivity and overcome myeloid-derived suppressor cells. Breast Cancer Res Treat, 142(1), 45–57.
- Ruan Q, Wang T, Kameswaran V, et al. (2011). The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta cell death. Proc Nat Acad Sci USA, 108(29), 12030–12035. doi:10.1073/pnas.1101450108.
- Singh M, Loftus T, Webb E, Benencia F. (2016). Minireview: Regulatory T cells and ovarian cancer. Immunol Invest, 45, 712–720. doi:10.1080/08820139.2016.1186689.
- St Rose MC, Taylor RA, Bandyopadhyay S, et al. (2013). CD134/CD137 dual costimulation-elicited IFN-gamma maximizes effector T-cell function but limits Treg expansion. Immunol Cell Biol, 91(2), 173–183. doi:10.1038/icb.2012.74.
- Sznurkowska K., Żawrocki A., Sznurkowski J., et al. (2016). Peripheral and intestinal T-regulatory cells are upregulated in children with inflammatory bowel disease at onset of disease. Immunol Invest, 45, 787–796.
- Wang K, Vella AT. (2016). Regulatory T cells and cancer: A two-sided story. Immunol Invest, 45, 797–812.
- Wang T, Shi W, Fan T, et al. (2016). c-Rel is required for the induction of pTregs in the eye but not in the gut mucosa. Immunol Invest, 45, 776–786. doi:10.3109/08820139.2016.1172639.
- Zang X, Jiang Y, Li X, et al. (2016). Characteristics of CD4+CD25+Foxp3+ regulatory T cells in patients with multiple organ dysfunction syndrome. Exp Ther Med, 11(5), 1908–1912. doi:10.3892/etm.2016.3157.